Teos Therapeutics downgraded to Hold after belrestotug failure and GSK deal ending. Read my updated analysis on ITOS stock ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...

Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...

GSK plc with its development partner iTeos Therapeutics, Inc., has announced that it is ending the development programme for ...

This follows what appeared to be a generally positive data readout for belrestotug at ESMO 2024 just a few months ago.

Belgian clinical-stage biotech iTeos Therapeutics (Nasdaq: ITOS) saw its shar leap18.6% to $8.20 today, despite posting ...

Teos Therapeutics, Inc. (NASDAQ:ITOS) reported topline results from an updated interim analysis of the GALAXIES Lung-201 ...

Teos Therapeutics faces significant setbacks with the discontinuation of their TIGIT program and belrestotug, leaving them ...

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

GSK said it is ending the development program for the small-molecule drug Belrestotug. The British pharmaceutical giant said Tuesday that the decision is based on a new interim analyses from phase 2 ...

Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...